Medicare AdvantagePrior AuthMedium impact
Sutent (sunitinib) (Revised)
Humana·Oncology, Hematology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jul 23, 2026
Summary
Humana revised its Sutent (sunitinib) prior authorization policy effective January 1, 2026, with updates finalized July 22, 2026. This pharmacy coverage policy establishes specific clinical criteria and exclusions for sunitinib approval across seven cancer indications (RCC adjuvant, thymomas/thymic carcinoma, GIST, advanced RCC, PNET, advanced thyroid carcinoma, and angiosarcoma). Key requirement: brand Sutent requests mandate documented intolerance or contraindication to generic sunitinib, and members with prior disease progression on sunitinib are excluded from coverage.
Action Required
By January 1, 2026: Billing team must implement prior authorization requirements for all Sutent (sunitinib) requests in the billing system. Specifically: (1) Configure system to require prior auth for brand Sutent versus generic sunitinib; (2) Create clinical criteria documentation checklist for oncology providers indicating: intolerance/contraindication to generic sunitinib, disease stage/progression status, and indication-specific clinical criteria (e.g., Stage T3+ for RCC adjuvant, imatinib failure for GIST); (3) Update encounter forms to require providers document prior sunitinib treatment history and any disease progression; (4) Train billing and provider staff on exclusion criteria, particularly the 54-week maximum for adjuvant RCC therapy; (5) Verify members do not have documented disease progression on prior sunitinib therapy before submitting authorization. Claims submitted without proper prior authorization or incomplete clinical documentation will be denied. Refer to www.humana.com/PAL for medical coding information.